Search Results - "Zuraw, Qing"

Clinical Trial of Vadadustat in Patients with Anemia Secondary to Stage 3 or 4 Chronic Kidney Disease by Martin, Edouard R, Smith, Mark T, Maroni, Bradley J, Zuraw, Qing C, deGoma, Emil M

“…Therapeutic options for the treatment of anemia secondary to chronic kidney disease (CKD) remain limited. Vadadustat (AKB-6548) is an oral hypoxia-inducible…”
Get more information

Guselkumab, an inhibitor of the IL-23p19 subunit, provides sustained improvement in signs and symptoms of active psoriatic arthritis: 1 year results of a phase III randomised study of patients who were biologic-naïve or TNFα inhibitor-experienced by Ritchlin, Christopher T, Helliwell, Philip S, Boehncke, Wolf-Henning, Soriano, Enrique R, Hsia, Elizabeth C, Kollmeier, Alexa P, Chakravarty, Soumya D, Zazzetti, Federico, Subramanian, Ramanand A, Xu, Xie L, Zuraw, Qing C, Sheng, Shihong, Jiang, Yusang, Agarwal, Prasheen, Zhou, Bei, Zhuang, Yanli, Shawi, May, Karyekar, Chetan S, Deodhar, Atul

“…ObjectiveEvaluation of the efficacy and safety of guselkumab, a human monoclonal antibody targeting the interleukin-23p19 subunit, in patients with psoriatic…”
Get full text

Evaluation of the LFA-REAL clinician-reported outcome (ClinRO) and patient-reported outcome (PRO): prespecified analysis of the phase III ustekinumab trial in patients with SLE by Askanase, Anca D, Tang, Wei, Zuraw, Qing, Gordon, Robert, Brotherton, Betsy, Merrill, Joan T

“…ObjectiveThe Lupus Foundation of America Rapid Evaluation of Activity in Lupus (LFA-REAL) system is a novel and simple SLE disease activity instrument,…”
Get full text

Generation of evidence supporting the content validity of SF-36, FACIT-F, and LupusQoL, and novel patient-reported symptom items for use in patients with systemic lupus erythematosus (SLE) and SLE with lupus nephritis (LN) by Williams-Hall, Rebecca, Berry, Pamela, Williamson, Nicola, Barclay, Melissa, Roberts, Anna, Gater, Adam, Tolley, Chloe, Bradley, Helena, Ward, Amy, Hsia, Elizabeth, Zuraw, Qing, DeLong, Patricia, Touma, Zahi, Strand, Vibeke

“…ObjectiveSLE and lupus nephritis (LN) have significant impacts on the health-related quality of life of patients living with the condition, which are important…”
Get full text

LP-195 Design of a Phase 2 study evaluating the efficacy and safety of nipocalimab in adult patients with active systemic lupus erythematosus by Liu-walsh, Fang, Bart van Hartingsveldt, Zuraw, Qing, Hoffman, Robert, Rooney, Terence, Gao, Sheng, Lee, YoungJa, Gordon, Robert, Leu, Jocelyn, Calderon, Cesar, Zazzetti, Federico, Stevens, Anne, Vratsanos, George

“…BackgroundSystemic lupus erythematosus (SLE) is a chronic, complex autoimmune disease characterized by pathogenic autoantibodies and tissue damage to multiple…”
Get full text

611 Efficacy and safety of nipocalimab in adult patients with active systemic lupus erythematosus: design of a phase 2 study by Liu-Walsh, Fang, Hartingsveldt, Bart van, Zuraw, Qing, Hoffman, Robert W, Rooney, Terence, Gao, Sheng, Gordon, Robert, Leu, Jocelyn H, Calderon, Cesar, Zazzetti, Federico, Stevens, Anne M, Vratsanos, George

“…BackgroundAutoantibody-mediated diseases, such as systemic lupus erythematosus (SLE), are caused by pathogenic antibodies that can damage tissues or organs…”
Get full text

Efficacy and Safety of Ustekinumab in Patients With Active Systemic Lupus Erythematosus: Results of a Phase II Open-label Extension Study by van Vollenhoven, Ronald F, Hahn, Bevra H, Tsokos, George C, Lipsky, Peter, Gordon, Robert M, Fei, Kaiyin, Lo, Kim Hung, Chevrier, Marc, Rose, Shawn, Berry, Pamela, Yao, Zhenling, Karyekar, Chetan S, Zuraw, Qing

“…To evaluate the long-term efficacy and safety of ustekinumab through 2 years in patients with active systemic lupus erythematosus (SLE). This was a…”
Get full text

MP418VADADUSTAT DOES NOT PROLONG CORRECTED QT INTERVAL IN A THOROUGH QTC STUDY IN HEALTHY SUBJECTS by McCullough, Peter, Weir, Matthew, deGoma, Emil, Zuraw, Qing, Sharma, Amit, Luo, Wenli, Middleton, John

Get full text

Towards a novel clinical outcome assessment for systemic lupus erythematosus: first outcomes of an international taskforce by Connelly, Kathryn, Eades, Laura E., Koelmeyer, Rachel, Ayton, Darshini, Golder, Vera, Kandane-Rathnayake, Rangi, Gregory, Kate, Brunner, Hermine, Burke, Laurie, Arnaud, Laurent, Askanase, Anca, Aranow, Cynthia, Vital, Ed, Pons-Estel, Guillermo, Dantata, Khadija, Andersen, Jeanette, Cornet, Alain, Buie, Joy, Sun, Ying, Tanaka, Yoshiya, Simon, Lee, Lahoud, Youmna, Friedman, Alan, Kalunian, Kenneth, Zuraw, Qing, Werth, Victoria, Garces, Sandra, Morand, Eric F.

“…Systemic lupus erythematosus (SLE) is a disease of high unmet therapeutic need. The challenge of accurately measuring clinically meaningful responses to…”
Get full text